Company / Shareholders' Equity
Protagonist Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$614.7M
FY2025
5-year range
$215.6M / $675.3M
FY2021-FY2025
Trend
-9.0%
vs FY2024
Sector context
#79 of 213
Health Care
What the data says
At $615M, Protagonist Therapeutics, Inc.'s shareholders' equity ranks #79 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $80M in FY2019 to $675M in FY2024.
Based on SEC 10-K filings.
$615M in FY2025 with a 5-year CAGR of +17.1%.
Improved from $337M to $615M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +41.8%
- 5-Year CAGR
- +17.1%
- 10-Year CAGR
- -
Sector benchmark
#79 of 213 in Health CareTop 37% of 213This company $614.7M Sector average $2.5B
▼
-75.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.1%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 9.0% year-over-year.
- Ranks #79 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $614.7M | -9.0% |
| FY2024 | $675.3M | +100.6% |
| FY2023 | $336.7M | +56.2% |
| FY2022 | $215.6M | -28.1% |
| FY2021 | $300.0M | +7.3% |
| FY2020 | $279.6M | +249.7% |
| FY2019 | $80.0M | -28.9% |
| FY2018 | $112.5M | -6.7% |
| FY2017 | $120.6M | +37.8% |
| FY2016 | $87.6M | +419.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026